Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were obs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Jumpei Akahane, Hiroshi Yamamoto, Masayuki Hanaoka
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	non-small cell lung cancer pembrolizumab adrenal insufficiency immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6c6b5dea8b844a03b042f08a23435fbf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c6b5dea8b844a03b042f08a23435fbf
record_format	dspace
spelling	oai:doaj.org-article:6c6b5dea8b844a03b042f08a23435fbf2021-12-02T12:40:22ZPembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series1662-657510.1159/000519597https://doaj.org/article/6c6b5dea8b844a03b042f08a23435fbf2021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519597https://doaj.org/toc/1662-6575Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE.Kei SoneharaKazunari TateishiTaisuke ArakiMasamichi KomatsuJumpei AkahaneHiroshi YamamotoMasayuki HanaokaKarger Publishersarticlenon-small cell lung cancerpembrolizumabadrenal insufficiencyimmune-related adverse eventsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1561-1566 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer pembrolizumab adrenal insufficiency immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer pembrolizumab adrenal insufficiency immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kei Sonehara Kazunari Tateishi Taisuke Araki Masamichi Komatsu Jumpei Akahane Hiroshi Yamamoto Masayuki Hanaoka Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
description	Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE.
format	article
author	Kei Sonehara Kazunari Tateishi Taisuke Araki Masamichi Komatsu Jumpei Akahane Hiroshi Yamamoto Masayuki Hanaoka
author_facet	Kei Sonehara Kazunari Tateishi Taisuke Araki Masamichi Komatsu Jumpei Akahane Hiroshi Yamamoto Masayuki Hanaoka
author_sort	Kei Sonehara
title	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
title_short	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
title_full	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
title_fullStr	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
title_full_unstemmed	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
title_sort	pembrolizumab-induced adrenal insufficiency in patients with untreated advanced non-small cell lung cancer: a case series
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/6c6b5dea8b844a03b042f08a23435fbf
work_keys_str_mv	AT keisonehara pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT kazunaritateishi pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT taisukearaki pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT masamichikomatsu pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT jumpeiakahane pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT hiroshiyamamoto pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries AT masayukihanaoka pembrolizumabinducedadrenalinsufficiencyinpatientswithuntreatedadvancednonsmallcelllungcanceracaseseries
_version_	1718393743137046528

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

Ejemplares similares